| Suzette Ann Denise Kilgore, MD | |
|
2300 Patterson St, Nashville, TN 37203-1538 | |
| (615) 342-1000 | |
| Not Available |
| Full Name | Suzette Ann Denise Kilgore |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 29 Years |
| Location | 2300 Patterson St, Nashville, Tennessee |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497724124 | NPI | - | NPPES |
| 08406750 | Medicaid | MS | |
| 1510860 | Medicaid | TN |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tristar Centennial Medical Center | Nashville, TN | Hospital |
| Sumner Regional Medical Center | Gallatin, TN | Hospital |
| Tristar Hendersonville Medical Center | Hendersonville, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Intensive Care Consortium Inc | 0244269413 | 370 |
| Anova Medical Associates | 8325372741 | 112 |
News Archive
The newest issue of the Journal of Urban Health: Bulletin of The New York Academy of Medicine includes a host of compelling research findings regarding risky sexual behavior in the vacation hotspot of Miami, racial influences on the quality of children's medical care, and willingness of blacks to use the Internet to manage their diabetes. These studies are summarized below.
Data from two Phase III studies of Merck's investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
Researchers at the Research Center for Immunotherapy and the Focus Program Translational Neurosciences of Johannes Gutenberg University Mainz have identified a new mechanism that is involved in the development of autoimmune diseases.
Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 1 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20151005002117 |
News Archive
The newest issue of the Journal of Urban Health: Bulletin of The New York Academy of Medicine includes a host of compelling research findings regarding risky sexual behavior in the vacation hotspot of Miami, racial influences on the quality of children's medical care, and willingness of blacks to use the Internet to manage their diabetes. These studies are summarized below.
Data from two Phase III studies of Merck's investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
Researchers at the Research Center for Immunotherapy and the Focus Program Translational Neurosciences of Johannes Gutenberg University Mainz have identified a new mechanism that is involved in the development of autoimmune diseases.
Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 1 days ago
| Entity Name | Anova Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659849537 PECOS PAC ID: 8325372741 Enrollment ID: O20190618003690 |
News Archive
The newest issue of the Journal of Urban Health: Bulletin of The New York Academy of Medicine includes a host of compelling research findings regarding risky sexual behavior in the vacation hotspot of Miami, racial influences on the quality of children's medical care, and willingness of blacks to use the Internet to manage their diabetes. These studies are summarized below.
Data from two Phase III studies of Merck's investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
Researchers at the Research Center for Immunotherapy and the Focus Program Translational Neurosciences of Johannes Gutenberg University Mainz have identified a new mechanism that is involved in the development of autoimmune diseases.
Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Suzette Ann Denise Kilgore, MD 2300 Patterson St Fl 4, Nashville, TN 37203-1538 Ph: (615) 372-6717 | Suzette Ann Denise Kilgore, MD 2300 Patterson St, Nashville, TN 37203-1538 Ph: (615) 342-1000 |
News Archive
The newest issue of the Journal of Urban Health: Bulletin of The New York Academy of Medicine includes a host of compelling research findings regarding risky sexual behavior in the vacation hotspot of Miami, racial influences on the quality of children's medical care, and willingness of blacks to use the Internet to manage their diabetes. These studies are summarized below.
Data from two Phase III studies of Merck's investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.
Researchers at the Research Center for Immunotherapy and the Focus Program Translational Neurosciences of Johannes Gutenberg University Mainz have identified a new mechanism that is involved in the development of autoimmune diseases.
Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.
Tranzyme Pharma announced positive top-line results today from a Phase 2, double-blind, placebo-controlled study evaluating TZP-102 capsules in diabetic patients with gastroparesis, a serious disorder characterized by the inability of the stomach to empty food efficiently. The study achieved a clinically meaningful and statistically significant improvement in critical gastroparesis-related symptoms. All three TZP-102 doses tested were effective, safe and well tolerated.
› Verified 1 days ago
Megan Desai, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4220 Harding Pike, Nashville, TN 37205 Phone: 615-222-6726 Fax: 615-222-3702 | |
Harrison Klause, Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
John N Bowers, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4230 Harding Pike Ste 500, Nashville, TN 37205 Phone: 629-255-2493 Fax: 629-255-4266 | |
Dr. Evan Zehr, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 1161 21st Ave S, Nashville, TN 37232 Phone: 615-322-6943 | |
Spurthi N Bhatt, MD MPH Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 3601 The Vanderbilt Clinic, Nashville, TN 37232 Phone: 615-322-3000 | |
Mr. Robert M Johnson, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 2410 Patterson St, Suite 106, Nashville, TN 37203 Phone: 615-340-4611 Fax: 615-340-4658 | |
Mr. John E Anderson, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 2400 Patterson St, Suite 400, Nashville, TN 37203 Phone: 615-342-5900 Fax: 615-342-5912 |